Aaron Rosenberg Biography and Net Worth

CFO of BeOne Medicines

Aaron Rosenberg joined BeOne in July 2024 as Chief Financial Officer.

Most recently, Mr. Rosenberg was Senior Vice President and Corporate Treasurer of Merck. Prior to his role as Corporate Treasurer, Mr. Rosenberg served as Senior Vice President of Corporate Strategy and Planning at Merck with responsibilities including leading the enterprise-wide business transformation team and acting as Head of Financial Planning & Analysis. Prior to that, Mr. Rosenberg was Vice President and Finance Lead of Merck Animal Health, leading a global team of 120 colleagues. He joined Merck in 2003 in ascending leadership roles in the global finance organization.

Mr. Rosenberg earned a B.S. in finance from the University of Florida and an MBA from New York University.

What is Aaron Rosenberg's net worth?: The estimated net worth of Aaron Rosenberg is at least $107.49 million as of June 11th, 2026. Mr. Rosenberg owns 397,891 shares of BeOne Medicines stock worth more than $107,490,254 as of June 20th. This net worth evaluation does not reflect any other assets that Mr. Rosenberg may own. Learn More about Aaron Rosenberg's net worth.
How do I contact Aaron Rosenberg?: The corporate mailing address for Mr. Rosenberg and other BeOne Medicines executives is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. BeOne Medicines can also be reached via phone at 13459494123 and via email at [email protected]. Learn More on Aaron Rosenberg's contact information.
Has Aaron Rosenberg been buying or selling shares of BeOne Medicines?: Within the last three months, Aaron Rosenberg has sold $162,633.94 in BeOne Medicines stock. Most recently, Aaron Rosenberg sold 631 shares of the business's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $257.74, for a transaction totalling $162,633.94. Following the completion of the sale, the chief financial officer now directly owns 397,891 shares of the company's stock, valued at $102,552,426.34. Learn More on Aaron Rosenberg's trading history.
Who are BeOne Medicines' active insiders?: BeOne Medicines' insider roster includes Margaret Dugan (Director), Chan Lee (SVP), John Oyler (CEO), Alessandro Riva (Director), Aaron Rosenberg (CFO), Corsee Sanders (Director), Corsee Sanders (Director), Lai Wang (Global Head of R&D), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeOne Medicines' active insiders.
Are insiders buying or selling shares of BeOne Medicines?: In the last twelve months, insiders at the sold shares 51 times. They sold a total of 351,635 shares worth more than $108,128,931.49. The most recent insider tranaction occured on June, 16th when COO Xiaobin Wu sold 1,357 shares worth more than $361,993.32. Insiders at BeOne Medicines own 6.2% of the company. Learn More about insider trades at BeOne Medicines.
Information on this page was last updated on 6/16/2026.

Aaron Rosenberg Insider Trading History at BeOne Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/11/2026	Sell	631	$257.74	$162,633.94	397,891
8/1/2025	Sell	1,190	$290.47	$345,659.30

Aaron Rosenberg Buying and Selling Activity at BeOne Medicines

BeOne Medicines Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Today's Range

Now: $270.15

$265.02

$274.55

50 Day Range

MA: $295.32

$260.27

$323.87

2 Week Range

Now: $270.15

$239.25

$385.22

Volume

367,884 shs

Average Volume

276,998 shs

Market Capitalization

$29.64 billion

P/E Ratio

60.44

Dividend Yield

N/A

Beta

0.49